Amyloid induced suicidal erythrocyte death.
Amyloid peptides are known to induce apoptosis in a wide variety of cells. Erythrocytes may similarly undergo suicidal death or eryptosis, which is characterized by scrambling of the cell membrane with subsequent exposure of phosphatidylserine (PS) at the cell surface. Eryptosis is triggered by increase of cytosolic Ca(2+) activity and by activation of acid sphingomyelinase with subsequent formation of ceramide. Triggers of eryptosis include energy depletion and isosmotic cell shrinkage (replacement of extracellular Cl(-) by impermeable gluconate for 24 h). The present study explored whether amyloid peptide Abeta (1-42) could trigger eryptosis and to possibly identify underlying mechanisms. Erythrocytes from healthy volunteers were exposed to amyloid and PS-exposure (annexin V binding), cell volume (forward scatter), cytosolic Ca(2+) activity (Fluo3 fluorescence) and ceramide formation (anti-ceramide antibody) were determined by FACS analysis. Exposure of erythrocytes to the amyloid peptide Abeta (1-42) (> or = 0.5 microM) for 24 h significantly triggered annexin V binding, an effect mimicked to a lesser extent by the amyloid peptide Abeta (1-40) (1 microM). Abeta (1-42) (> or = 1.0 microM) further significantly decreased forward scatter of erythrocytes. The effect of Abeta (1-42) (> or = 0.5 microM) on erythrocyte annexin V binding was paralleled by formation of ceramide but not by significant increase of cytosolic Ca(2+) activity. The presence of Abeta (1-42) further significantly enhanced the eryptosis following Cl(-) depletion but not of glucose depletion for 24 hours. The present observations disclose a novel action of Abeta (1-42), which may well contribute to the pathophysiological effects of amyloid peptides, such as vascular complications in Alzheimer's disease.
Nicolay
Jan P
JP
Department of Physiology, University of Tübingen, Tübingen, Germany.
Gatz
Sabine
S
Liebig
Gerd
G
Gulbins
Erich
E
Lang
Florian
F
D016229:Amyloid beta-Peptides / Q000494:pharmacology*; D017304:Annexin A5; D017209:Apoptosis; D002118:Calcium / Q000502:physiology; D002518:Ceramides / Q000096:biosynthesis; D002712:Chlorides / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004912:Erythrocytes / Q000187:drug effects*; D005947:Glucose / Q000378:metabolism; D006801:Humans; D010446:Peptide Fragments / Q000494:pharmacology*; D010718:Phosphatidylserines / Q000494:pharmacology
D016229:Amyloid beta-Peptides; D017304:Annexin A5; D002518:Ceramides; D002712:Chlorides; D010446:Peptide Fragments; D010718:Phosphatidylserines; D005947:Glucose; D002118:Calcium